Brief: India's SPARC Licenses Commercialization Rights Of Epilepsy Drug To Tripoint Therapeutics

Sun Pharma Advanced Research

22/09/2020 04:08

Sept 22 (Reuters) - Sun Pharma Advanced Research Co Ltd
 SPRC.NS :
    * SUN PHARMA ADVANCED RESEARCH - LICENSES COMMERCIALIZATION
RIGHTS
OF ELEPSIA XR TO TRIPOINT THERAPEUTICS
    * SUN PHARMA ADVANCED RESEARCH - UNDER TERMS, CO TO RECEIVE
ROYALTIES RANGING FROM 15-50% ON NET SALE
    * SUN PHARMA ADVANCED RESEARCH - TRIPOINT TO BE RESPONSIBLE
FOR
ALL U.S. REGULATORY SUBMISSIONS FOR ELEPSIA
    * SUN PHARMA ADVANCED RESEARCH - TRIPOINT TO ALSO BE
RESPONSIBLE
FOR PAYMENT OF ANNUAL PDUFA FEES FOR ELEPSIA
    * SUN PHARMA ADVANCED RESEARCH - INITIAL TERM OF PACT SHALL
BE 5
YEARS
    * SUN PHARMA ADVANCED RESEARCH - PACT MAY BE FURTHER
EXTENDED

Source text for Eikon:  ID:nBSE69DfC9 
Further company coverage:  SPRC.NS 

 ((Reuters.Briefs@thomsonreuters.com;))